Aller au contenu

Rewind: Melanoma Meltdowns, Biosimilar Betrayals, and the Eczema Enigma Exposed!

29 mai 2026 · 1 h 1 min

Notes de l’épisode

Melanoma, Anxiety, and Depression Links; Biosimilars vs Humira; Air Pollution and Atopic Dermatitis – Have We Finally Figured Out Why Eczema Is So Common and much, much more…

  • Which patients are the most affected by anxiety and depression after a melanoma diagnosis and what can we do about it?
  • Patients who are switched onto a biosimilar do “worse” than patients who start one as their first therapy – why?
  • We finally got eczema answers. Turns out that air pollution, both indoor and outdoor, is the cause of the atopic dermatitis epidemic that started in the 1970s and is why eczema is more common in urban areas.
  • Ian Myles explains how he proved that air pollution is the driving force behind atopic dermatitis and helps our team understand what it all means
  • Plus: Predictors of acne relapse after isotretinoin, dupilumab prevents cancer, how well does tralokinumab work in dupilumab "failures," ferulic acid for rosacea, cysteamine vs hydroquinone for melasma, and the best way to treat digital mucous cysts

Guest: Ian A. Myles, MD, Mph

Dr. Myles, Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. He worked under the mentorship of Dr. Sandip Datta investigating the mechanistic details of susceptibility to S. aureus skin infections. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. LCDR Myles has supported several USPHS missions, from the Ebola virus vaccine trial in West Africa to congressional Gold Medal Ceremonies at the U.S. Capitol. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs.

Tous les épisodes de Derms on Drugs

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.